Skip to main content
Erschienen in: Annals of Hematology 3/2008

01.03.2008 | Original Article

Cholesterol levels in patients with multiple myeloma

verfasst von: Irfan Yavasoglu, Murat Tombuloglu, Gurhan Kadikoylu, Ayhan Donmez, Seckin Cagırgan, Zahit Bolaman

Erschienen in: Annals of Hematology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Hypocholesterolemia is seen in solid tumors and some hematological malignancies. We assessed cholesterol levels and the relationship between these levels and types and stages of multiple myeloma (MM) in the patients with MM. One-hundred two patients (60 male and 42 female) of mean age 59 ± 11 years with MM were enrolled to this study. While 71.6% of the patients were Ig G type, 80.4% of the patients were at stage III. In the control group, there were 71 healthy persons (42 male and 29 female) of mean age 58 ± 8 years. The levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in the patients with MM were significantly lower than the controls (p < 0.001). There was no difference for the levels of very-low-density lipoprotein cholesterol and triglyceride between the two groups (p > 0.05). Lipid parameters were not different between Ig types (p > 0.05). The levels of TC and LDL-C in the patients with stage I were higher than those of stages II and III (p < 0.001 and p < 0.005, respectively). The levels of TC and LDL-C in the controls were not higher than the patients with stage I (p > 0.05). HDL-C levels in the patients with stage III were lower than controls (p < 0.001). Hypocholesterolemia are seen in the patients with MM. Hypocholesterolemia may be due to increased LDL clearance and utilization of cholesterol by myeloma cells.
Literatur
1.
Zurück zum Zitat Castelli WP (1984) Epidemiology of coronary heart disease. The Framingham study. Am J Med 76:4–12PubMedCrossRef Castelli WP (1984) Epidemiology of coronary heart disease. The Framingham study. Am J Med 76:4–12PubMedCrossRef
2.
Zurück zum Zitat Ginsberg HN, Goldberg IJ (1998) Disorders of lipoprotein metabolism. In: Fauci SA, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper LD, Hauser LS, Longo LD (eds) Harrison’s principles internal medicine, 14st edn. Mcgraw-Hill, New York, pp 2138–2149 Ginsberg HN, Goldberg IJ (1998) Disorders of lipoprotein metabolism. In: Fauci SA, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper LD, Hauser LS, Longo LD (eds) Harrison’s principles internal medicine, 14st edn. Mcgraw-Hill, New York, pp 2138–2149
3.
Zurück zum Zitat Muller G, Schilf K (1987) Hypocholestreolemia. Z Gesamte Inn Med 42:310–313 (Abstract)PubMed Muller G, Schilf K (1987) Hypocholestreolemia. Z Gesamte Inn Med 42:310–313 (Abstract)PubMed
4.
Zurück zum Zitat Tomiki Y, Suda S, Tanaka M, Okuzawa A, Matsuda M, Ishibiki Y, Sakamato K, Kamano T, Tsurumaru M, Watanabe Y (2004) Reduced low-density-lipoprotein cholesterol causing low serum cholesterol levels in gastrointestinal cancer: a case control study. J Exp Clin Cancer Res 23:233–240PubMed Tomiki Y, Suda S, Tanaka M, Okuzawa A, Matsuda M, Ishibiki Y, Sakamato K, Kamano T, Tsurumaru M, Watanabe Y (2004) Reduced low-density-lipoprotein cholesterol causing low serum cholesterol levels in gastrointestinal cancer: a case control study. J Exp Clin Cancer Res 23:233–240PubMed
5.
Zurück zum Zitat Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H (2000) Serum total cholesterol and triglycerides levels in patients with lung cancer. Int J Mol Med 5:201–205PubMed Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H (2000) Serum total cholesterol and triglycerides levels in patients with lung cancer. Int J Mol Med 5:201–205PubMed
6.
Zurück zum Zitat Gadomska H, Janecki J, Marianowski L, Nowicka G (1997) Lipids in serum of patients with malignant ovarian neoplasms. Int J Gynaecol Obstet 57:287–293PubMedCrossRef Gadomska H, Janecki J, Marianowski L, Nowicka G (1997) Lipids in serum of patients with malignant ovarian neoplasms. Int J Gynaecol Obstet 57:287–293PubMedCrossRef
7.
Zurück zum Zitat Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA, Nelson JA (1983) The dual role of mevalonate in cell cycle. J Biol Chem 258:378–385PubMed Quesney-Huneeus V, Galick HA, Siperstein MD, Erickson SK, Spencer TA, Nelson JA (1983) The dual role of mevalonate in cell cycle. J Biol Chem 258:378–385PubMed
8.
Zurück zum Zitat Gal D, Ottashi M, Macdonald PC, Buschbaum HJ, Simpson ER (1981) Low density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol 139:877–885PubMed Gal D, Ottashi M, Macdonald PC, Buschbaum HJ, Simpson ER (1981) Low density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol 139:877–885PubMed
9.
Zurück zum Zitat Niendorf A, Nagele H, Gerding D, Meyer-Pannwitt U, Gebhardt A (1995) Increased LDL receptor mRNA expression in colon cancer is correlated with rise in plasma cholesterol levels after curative surgery. Int J Cancer 6:461–464CrossRef Niendorf A, Nagele H, Gerding D, Meyer-Pannwitt U, Gebhardt A (1995) Increased LDL receptor mRNA expression in colon cancer is correlated with rise in plasma cholesterol levels after curative surgery. Int J Cancer 6:461–464CrossRef
10.
Zurück zum Zitat Vassiliou G, Benoist F, Lau P, Kavaslar GN, Mcpherson P (2001) The low density lipoprotein receptor-related protein contributes to selective uptake of HDL-cholesteryl esters by Sw872 liposarcoma cells and primary human adipocytes. J Biol Chem 276:48823–48830PubMedCrossRef Vassiliou G, Benoist F, Lau P, Kavaslar GN, Mcpherson P (2001) The low density lipoprotein receptor-related protein contributes to selective uptake of HDL-cholesteryl esters by Sw872 liposarcoma cells and primary human adipocytes. J Biol Chem 276:48823–48830PubMedCrossRef
11.
Zurück zum Zitat Peterson C, Vitols S, Rudling M, Blomgren H, Edsmyr F, Skoog L (1985) Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med Oncol Tumor Pharmacother 2:143–147PubMed Peterson C, Vitols S, Rudling M, Blomgren H, Edsmyr F, Skoog L (1985) Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med Oncol Tumor Pharmacother 2:143–147PubMed
12.
Zurück zum Zitat Allampallam K, Dutt D, Nair C, Shetty V, Mundle S, Lisak L, Andrews C, Ahmed B, Mazzone L, Zorat F, Borok R, Muzammil M, Gundroo A, Ansaarie I, Raza A (2000) The clinical and biological significance of abnormal lipid profiles in patients with myelodysplastic syndromes. J Hematother Stem Cells 9:247–255CrossRef Allampallam K, Dutt D, Nair C, Shetty V, Mundle S, Lisak L, Andrews C, Ahmed B, Mazzone L, Zorat F, Borok R, Muzammil M, Gundroo A, Ansaarie I, Raza A (2000) The clinical and biological significance of abnormal lipid profiles in patients with myelodysplastic syndromes. J Hematother Stem Cells 9:247–255CrossRef
13.
Zurück zum Zitat Goncalves RP, Rodrigues DG, Maranhao RC (2005) Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk Res 29:955–959PubMedCrossRef Goncalves RP, Rodrigues DG, Maranhao RC (2005) Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk Res 29:955–959PubMedCrossRef
14.
Zurück zum Zitat Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (1997) Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity. Am J Hematol 55:129–133PubMedCrossRef Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (1997) Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity. Am J Hematol 55:129–133PubMedCrossRef
15.
Zurück zum Zitat Musolino C, Calabro L, Bellomo G, Cincotta M, Di Giacomo V, Pezzano C, Loteta B, Rizzo B, Guglielmo S, Alonci A (2002) Lipid profile in hematologic neoplasms. Recenti Prog Med 93:298–301 (Abstract)PubMed Musolino C, Calabro L, Bellomo G, Cincotta M, Di Giacomo V, Pezzano C, Loteta B, Rizzo B, Guglielmo S, Alonci A (2002) Lipid profile in hematologic neoplasms. Recenti Prog Med 93:298–301 (Abstract)PubMed
16.
Zurück zum Zitat Rudling M, Gafvels M, Parini P, Gahrton G, Angelin B (1998) Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation. Am J Pathol 153:1923–1935PubMed Rudling M, Gafvels M, Parini P, Gahrton G, Angelin B (1998) Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation. Am J Pathol 153:1923–1935PubMed
17.
Zurück zum Zitat Tatidis L, Vitols S, Bruber A, Paul C, Axelson M (2001) Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of circulating marker for bile acid synthesis. Cancer Letters 170:169–175PubMedCrossRef Tatidis L, Vitols S, Bruber A, Paul C, Axelson M (2001) Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of circulating marker for bile acid synthesis. Cancer Letters 170:169–175PubMedCrossRef
18.
Zurück zum Zitat Aviram M, Brook JG, Tatarsky I, Levy Y, Carter A (1986) Increased low density lipoprotein levels after splenectomy: a role for the spleen in cholesterol metabolism in myeloproliferative disorders. Am J Med Sci 29:25–28CrossRef Aviram M, Brook JG, Tatarsky I, Levy Y, Carter A (1986) Increased low density lipoprotein levels after splenectomy: a role for the spleen in cholesterol metabolism in myeloproliferative disorders. Am J Med Sci 29:25–28CrossRef
19.
Zurück zum Zitat Dispenzeri A, Lacy MQ, Greipp PR (2004) Multiple myeloma. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B (eds) Wintrobe’s clinical hematology, 11st edn. Lippincott Williams–Wilkins, Philadelphia, pp 2583–2636 Dispenzeri A, Lacy MQ, Greipp PR (2004) Multiple myeloma. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B (eds) Wintrobe’s clinical hematology, 11st edn. Lippincott Williams–Wilkins, Philadelphia, pp 2583–2636
20.
Zurück zum Zitat Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Baccadora M (2004) New drugs for treatment of multiple myeloma. Lancet Oncol 5:430–442PubMedCrossRef Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Baccadora M (2004) New drugs for treatment of multiple myeloma. Lancet Oncol 5:430–442PubMedCrossRef
21.
Zurück zum Zitat Li JL, Li YJ, Chao YJ, Lin LX, Ouyang MH, Peng YB, Chang WS (1991) Cholesterol requirement for growth of Ir983f and P3x63-Ag8-U1 myeloma cells in serum-free medium. Cytobios 68:15–22PubMed Li JL, Li YJ, Chao YJ, Lin LX, Ouyang MH, Peng YB, Chang WS (1991) Cholesterol requirement for growth of Ir983f and P3x63-Ag8-U1 myeloma cells in serum-free medium. Cytobios 68:15–22PubMed
22.
Zurück zum Zitat Sato JD, Kawamoto T, Okamoto T (1987) Cholesterol requirement of P3-X63-Ag8 and X63-Ag8.653 mouse myeloma cells for growth in vitro. J Exp Med 165:1761–1766PubMedCrossRef Sato JD, Kawamoto T, Okamoto T (1987) Cholesterol requirement of P3-X63-Ag8 and X63-Ag8.653 mouse myeloma cells for growth in vitro. J Exp Med 165:1761–1766PubMedCrossRef
23.
Zurück zum Zitat Aixala M, Sarandria CN, Speroni JG (1997) Hypocholesterolemia in hematologic neoplasms. Sangre 42:7–10 (Abstract)PubMed Aixala M, Sarandria CN, Speroni JG (1997) Hypocholesterolemia in hematologic neoplasms. Sangre 42:7–10 (Abstract)PubMed
24.
Zurück zum Zitat Scolozzi R, Boccafogli A, Salmi R, Furlani MR, Guidoboni CA, Vicentini L, Coletti M, Tocchetto M (1983) Hypocholesterolemia in multiple myeloma. Inverse relation to the component M and the clinical stage. Minerva Med 74:2359–2364 (Abstract)PubMed Scolozzi R, Boccafogli A, Salmi R, Furlani MR, Guidoboni CA, Vicentini L, Coletti M, Tocchetto M (1983) Hypocholesterolemia in multiple myeloma. Inverse relation to the component M and the clinical stage. Minerva Med 74:2359–2364 (Abstract)PubMed
25.
Zurück zum Zitat Hachem H, Favre G, Ghalim N, Puchois P, Fruchart JC, Soula G (1987) Quantitative abnormalities of lipoprotein particles in multiple myeloma. J Clin Chem Clin Biochem 25:675–679PubMed Hachem H, Favre G, Ghalim N, Puchois P, Fruchart JC, Soula G (1987) Quantitative abnormalities of lipoprotein particles in multiple myeloma. J Clin Chem Clin Biochem 25:675–679PubMed
26.
Zurück zum Zitat Levy Y, Aviram M, Spira G, Tatarsky I, Brook GJ, Carter A (1984) Plasma cholesterol concentration and extra lipid band in monoclonal gammopathies. Postgraduate Med J 60:449–453CrossRef Levy Y, Aviram M, Spira G, Tatarsky I, Brook GJ, Carter A (1984) Plasma cholesterol concentration and extra lipid band in monoclonal gammopathies. Postgraduate Med J 60:449–453CrossRef
27.
Zurück zum Zitat Van De Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16:1362–1371PubMedCrossRef Van De Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16:1362–1371PubMedCrossRef
28.
Zurück zum Zitat Gronich N, Drucker L, Shapiro H, Radnay J, Yarkoni S, Lishner M (2004) Simvastatin induces death of multiple myeloma cell lines. J Investig Med 52:335–344PubMedCrossRef Gronich N, Drucker L, Shapiro H, Radnay J, Yarkoni S, Lishner M (2004) Simvastatin induces death of multiple myeloma cell lines. J Investig Med 52:335–344PubMedCrossRef
29.
Zurück zum Zitat Van Der Spek E, Bloem AC, Van De Donk NW, Rogers LH, Van Der Griend R, Kramer MH, De Weerdt O, Wittebol S, Lokhorst HM (2006) Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 91:542–545PubMed Van Der Spek E, Bloem AC, Van De Donk NW, Rogers LH, Van Der Griend R, Kramer MH, De Weerdt O, Wittebol S, Lokhorst HM (2006) Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 91:542–545PubMed
30.
Zurück zum Zitat International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol 121:749–757CrossRef International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol 121:749–757CrossRef
31.
Zurück zum Zitat Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854PubMedCrossRef Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854PubMedCrossRef
32.
Zurück zum Zitat Friedewald WT, Levy RI, Fredrikson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:449–502 Friedewald WT, Levy RI, Fredrikson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:449–502
33.
Zurück zum Zitat Mahley RW, Weisgraber KH, Farese RV (1998) Disorders of lipid metabolism. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds) Williams textbook of endocrinology, 9th edn. Saunders, Philadelphia, pp 1099–1153 Mahley RW, Weisgraber KH, Farese RV (1998) Disorders of lipid metabolism. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds) Williams textbook of endocrinology, 9th edn. Saunders, Philadelphia, pp 1099–1153
34.
Zurück zum Zitat Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhao RC (2004) Metabolism of a cholesterol-rich microemulsion (Lde) in patients with multiple myeloma and a preliminary clinical study of Lde as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 53:51–60PubMed Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhao RC (2004) Metabolism of a cholesterol-rich microemulsion (Lde) in patients with multiple myeloma and a preliminary clinical study of Lde as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 53:51–60PubMed
35.
Zurück zum Zitat Tsuchiya J (1989) Some problems in the laboratory findings in multiple myeloma. Nippon Ketsueki Gakkai Zasshi 52:1273–1278 (Abstract)PubMed Tsuchiya J (1989) Some problems in the laboratory findings in multiple myeloma. Nippon Ketsueki Gakkai Zasshi 52:1273–1278 (Abstract)PubMed
36.
Zurück zum Zitat Osadchy A, Drucker L, Radnay J, Shapira H, Lishner M (2004) Microenvironment factors do not afford myeloma cell lines protection from simvastatin. Eur J Haematol 73:183–190PubMedCrossRef Osadchy A, Drucker L, Radnay J, Shapira H, Lishner M (2004) Microenvironment factors do not afford myeloma cell lines protection from simvastatin. Eur J Haematol 73:183–190PubMedCrossRef
37.
Zurück zum Zitat Van De Donk NW, Lokhorst HM, Nijhuis EH, Kamphuis MM, Bloem EC (2005) Geranylgeranylated proteins are involvedin the regulation of myeloma cell growth. Clin Cancer Res 11:429–439PubMed Van De Donk NW, Lokhorst HM, Nijhuis EH, Kamphuis MM, Bloem EC (2005) Geranylgeranylated proteins are involvedin the regulation of myeloma cell growth. Clin Cancer Res 11:429–439PubMed
38.
Zurück zum Zitat Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini E (2000) Non-lipid related effects of statins. Ann Med 32:164–176PubMed Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini E (2000) Non-lipid related effects of statins. Ann Med 32:164–176PubMed
39.
Zurück zum Zitat Thibault A, Samid D, Tompkins AC, Wigg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway in patients with cancer. Clin Cancer Res 2:483–491PubMed Thibault A, Samid D, Tompkins AC, Wigg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway in patients with cancer. Clin Cancer Res 2:483–491PubMed
40.
Zurück zum Zitat Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK (2001) Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19:81–83PubMedCrossRef Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK (2001) Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19:81–83PubMedCrossRef
Metadaten
Titel
Cholesterol levels in patients with multiple myeloma
verfasst von
Irfan Yavasoglu
Murat Tombuloglu
Gurhan Kadikoylu
Ayhan Donmez
Seckin Cagırgan
Zahit Bolaman
Publikationsdatum
01.03.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 3/2008
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-007-0375-6

Weitere Artikel der Ausgabe 3/2008

Annals of Hematology 3/2008 Zur Ausgabe

Review Article

Iron and thrombosis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.